| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DTIL Stock Overview
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States.
Precision BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$14.38 |
| 52 Week Low | US$1.11 |
| Beta | 1.56 |
| 1 Month Change | 45.07% |
| 3 Month Change | 9.00% |
| 1 Year Change | -78.32% |
| 3 Year Change | -78.89% |
| 5 Year Change | n/a |
| Change since IPO | -88.19% |
Recent News & Updates
Precision BioSciences Q2 2022 Earnings Preview
Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$0.46 (-227.8% Y/Y) and the consensus Revenue Estimate is $5.11M (-92.6% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
Shareholder Returns
| DTIL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.0% | 1.4% | 3.6% |
| 1Y | -78.3% | -19.6% | -9.6% |
Return vs Industry: DTIL underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: DTIL underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| DTIL volatility | |
|---|---|
| DTIL Average Weekly Movement | 18.2% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: DTIL is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: DTIL's weekly volatility has increased from 13% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 192 | Michael Amoroso | https://www.precisionbiosciences.com |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
Precision BioSciences, Inc. Fundamentals Summary
| DTIL fundamental statistics | |
|---|---|
| Market Cap | US$228.29m |
| Earnings (TTM) | -US$92.77m |
| Revenue (TTM) | US$37.51m |
6.1x
P/S Ratio-2.5x
P/E RatioIs DTIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DTIL income statement (TTM) | |
|---|---|
| Revenue | US$37.51m |
| Cost of Revenue | US$0 |
| Gross Profit | US$37.51m |
| Other Expenses | US$130.28m |
| Earnings | -US$92.77m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -247.31% |
| Debt/Equity Ratio | 21.5% |
How did DTIL perform over the long term?
See historical performance and comparison